(Q30385239)

15 September 2017

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. (English)

1 reference

15 September 2017

John S Tokarski

1

1 reference

15 September 2017

Adriana Zupa-Fernandez

2

1 reference

15 September 2017

Jeffrey A Tredup

3

1 reference

15 September 2017

Kristen Pike

4

1 reference

15 September 2017

ChiehYing Chang

5

1 reference

15 September 2017

Dianlin Xie

6

1 reference

15 September 2017

Lihong Cheng

7

1 reference

15 September 2017

Donna Pedicord

8

1 reference

15 September 2017

Jodi Muckelbauer

9

1 reference

15 September 2017

Stephen R Johnson

10

1 reference

15 September 2017

Sophie Wu

11

1 reference

15 September 2017

Suzanne C Edavettal

12

1 reference

15 September 2017

Yang Hong

13

1 reference

15 September 2017

Mark R Witmer

14

1 reference

15 September 2017

Lisa L Elkin

15

1 reference

15 September 2017

Yuval Blat

16

1 reference

15 September 2017

William J Pitts

17

1 reference

15 September 2017

David S Weinstein

18

1 reference

15 September 2017

James R Burke

19

1 reference

15 September 2017

language of work or name

English

0 references

publication date

11 March 2015

1 reference

Journal of Biological Chemistry

15 September 2017

1 reference

15 September 2017

290

1 reference

15 September 2017

17

1 reference

15 September 2017

11061-11074

1 reference

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Targeting IL-17 and TH17 cells in chronic inflammation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Comprehensive analysis of kinase inhibitor selectivity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

REFMAC5 for the refinement of macromolecular crystal structures

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Trends in kinase selectivity: insights for target class-focused library screening

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Pseudokinases-remnants of evolution or key allosteric regulators?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Features and development of Coot

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Phasercrystallographic software

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Do enthalpy and entropy distinguish first in class from best in class?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Differential regulation of STAT family members by glycogen synthase kinase-3

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

The JAK-STAT signaling pathway: input and output integration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

The V617F JAK2 mutation and the myeloproliferative disorders

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4409266

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

20 June 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Novel tricyclic inhibitors of IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M114.619502

Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence

21 January 2018

1 reference

12 December 2020

A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses

1 reference

12 December 2020

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis

1 reference

12 December 2020

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

1 reference

12 December 2020

Processing of X-ray diffraction data collected in oscillation mode

1 reference

12 December 2020

Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry

1 reference

12 December 2020

Identifiers

DOI

10.1074/JBC.M114.619502

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

25762719

1 reference